test3

Attention Virginia Cancer Specialists Patients: There is a system outage and certain functions, such as scheduling, may not be available today. We will call patients to schedule any upcoming appointments when the system is back online. Our clinics remain open and previously scheduled appointments will continue as planned. We apologize for any inconvenience.

 

Anne Favret, M.D., Co Author for the New England Journal of Medicine Advanced Breast Cancer Study

Virginia Cancer Specialists Practice Blog

October 14, 2016
Virginia Cancer Specialists » VCS Practice News » Cancer Types » VCS Practice News » Breast Cancer » Anne Favret, M.D., Co Author for the New England Journal of Medicine Advanced Breast Cancer Study

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer – Co Author Anne M Favret

New England Journal of Medicine.

This phase 3 trial showed significant prolongation of progression-free survival and higher rates of overall response with the addition of ribociclib to letrozole than with the addition of placebo to letrozole for first-line treatment in postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The improvement in the duration of progression-free survival was associated with a higher rate of myelosuppression among patients in the ribociclib group.

Anne Favret, MD

Anne Favret, M.D

Schedule An Appointment Here